arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BioCardia, Inc.

BCDA
$0.98 ▲ +0.02 (+2.27%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
66 Visible periods
28 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, BioCardia, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $10.6M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC 167.9%
FCF / Share $-0.15
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-2.26M
↑ +16.7%
Operating Margin Operating profit as % of sales
-256.3%
↑ +22.3%
FCF / Share Free cash flow per share
$-0.15
↑ +56.0%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -730.7% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.90x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters